Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease.

doi:10.1111/j.1523-1755.2005.00554.x

Paper

Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease.

Published Oct 1, 2005 · DOI · M. Rao, B. Pereira

Kidney international

65

Citations

1

Influential Citations

PDF

Abstract

Anemia is a frequent complication of chronic kidney disease, occurring in over 90% of patients undergoing renal replacement therapy. The pathogenesis of the anemia of chronic kidney disease is multifactorial, but the predominant and most consistent cause is the failure of adequate production of endogenous erythropoietin (EPO) by the kidneys. Anemia is seen early in the course of chronic kidney disease, the decline in hemoglobin concentration starting at levels of creatinine clearance of around 70 mL/min among men and 50 mL/min among women1. The fundamental impact of anemia on organ function is reduced oxygen delivery to tissues. Fatigue and effort intolerance are the cardinal symptoms, but other consequences such as impaired cognitive function and concentration, sleep disorders, altered hemostasis, depressed immune function, and impaired cardiac function are not uncommon.

Study Snapshot

Optimal anemia management in chronic kidney disease patients reduces cardiovascular morbidity, mortality, and costs, while improving fatigue, cognitive function, and sleep disorders.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease.

References

Citations